May 24, 2017 4:25 AM ET


Company Overview of Exosome Diagnostics, Inc.

Company Overview

Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company develops exosome-based diagnostics technology platform that harvests comprehensive and dynamic molecular information contained within exosomes from various fresh or frozen biofluids to deliver personalized healthcare to guide treatment decisions and in real-time along the entire patient care continuum. Its technology combines RNA analysis with DNA and protein analysis to deliver comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated, and monitored. The company al...

Riverside Technology Center

840 Memorial Drive

Suite 3

Cambridge, MA 02139

United States

Founded in 2008





Key Executives for Exosome Diagnostics, Inc.

Chief Executive Officer and President
Chief Financial Officer
Age: 45
Chief Science Officer and Founding Scientist
Head of Informatics
Head of Commercial Diagnostics
Compensation as of Fiscal Year 2016.

Exosome Diagnostics, Inc. Key Developments

Exosome Diagnostics Signs an Agreement with Merck to Help Advance the Development of New Drugs

Exosome Diagnostics has signed an agreement with Merck to help advance the development of new drugs in oncology and other therapeutic areas using the former’s proprietary technology platforms that span across nucleic acid and protein.

Exosome Diagnostics, Inc. Obtains ISO 15189 for its Munich Laboratory

Exosome Diagnostics, Inc. announced that it has received ISO 15189 certification for its Munich laboratory, thereby paving the way to process clinical samples in Asia, Europe, the Middle East, and Russia, more efficiently. Combined with the company’s CLIA certified Cambridge laboratory, the Munich laboratory and offices will serve as an integral part of the company’s diagnostic strategy to better the lives of patients worldwide. In September 2016, Exosome Diagnostics launched its diagnostic test for prostate cancer, ExoDx Prostate Intelliscore (EPI), to determine whether a patient who presented with a PSA in the gray zone needed to proceed with a biopsy. In the United States each year, approximately one million prostate biopsies are performed with up to 80% of the results indicating no cancer, or a low-grade cancer that could instead be monitored under a watchful waiting or active surveillance program. The EPI test was designed to reduce the number of unnecessary prostate biopsies and the associated overtreatment of low-grade disease. Complications associated with unnecessary prostate tissue biopsies range from discomfort and temporary incontinence or impotence, to hospitalization for serious infections in three to four percent of patients.

Exosome Diagnostics, Inc. Presents at 19th Annual BIO CEO & Investor Conference, Feb-13-2017

Exosome Diagnostics, Inc. Presents at 19th Annual BIO CEO & Investor Conference, Feb-13-2017 . Venue: The Waldorf Astoria New York, 301 Park Avenue, New York, NY 10022, United States.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Exosome Diagnostics, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at